Search Results - "Colson, Kathleen"

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial by RICHARDSON, Paul G, WOLF, Jeff, MARTIN, Tom, SCHLOSSMAN, Robert, GHOBRIAL, Irene M, MUNSHI, Nikhil, LAUBACH, Jacob, ALLERTON, Jeff, HIDESHIMA, Teru, COLSON, Kathleen, PORADOSU, Enrique, GARDNER, Lesa, JAKUBOWIAK, Andrzej, SPORTELLI, Peter, ANDERSON, Kenneth C, ZONDER, Jeff, LONIAL, Sagar, IRWIN, David, DENSMORE, John, KRISHNAN, Amrita, RAJE, Noopur, BAR, Michael

“…Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction…”
Get full text

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma by Laubach, Jacob P., Tuchman, Sascha A., Rosenblatt, Jacalyn M., Mitsiades, Constantine S., Colson, Kathleen, Masone, Kelly, Warren, Diane, Redd, Robert A., Grayson, Dena, Richardson, Paul G.

“…Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation…”
Get full text

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib by Richardson, Paul G., Nagler, Arnon, Ben‐Yehuda, Dina, Badros, Ashraf, Hari, Parameswaran N., Hajek, Roman, Spicka, Ivan, Kaya, Hakan, LeBlanc, Richard, Yoon, Sung‐Soo, Kim, Kihyun, Martinez‐Lopez, Joaquin, Mittelman, Moshe, Shpilberg, Ofer, Blake, Paul, Hideshima, Teru, Colson, Kathleen, Laubach, Jacob P., Ghobrial, Irene M., Leiba, Merav, Gatt, Moshe E., Sportelli, Peter, Chen, Michael, Anderson, Kenneth C.

“…Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including…”
Get full text

Treatment-related symptom management in patients with multiple myeloma: a review by Colson, Kathleen

“…Purpose Recent therapeutic advancements have significantly improved overall survival of patients with multiple myeloma (MM). As a result, the impact of…”
Get full text

Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma by Noonan, Kimberly, Colson, Kathleen

“…To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). Journal…”
Get full text

Isatuximab by Wilmoth, Jenai, Colson, Kathleen, Dubin, Franck, Kellam, Christine

“…BACKGROUND: Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with…”
Get full text

MM-053: Nursing Considerations for the Use of Isatuximab in the Treatment of Multiple Myeloma by Wilmoth, Jenai, Colson, Kathleen, Dubin, Franck, Kellam, Christine

“…Isatuximab (Isa) is a monoclonal antibody that binds to a specific epitope on CD38 and triggers death of multiple myeloma (MM) cells. Isatuximab-irfc is…”
Get full text

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, Anderson, Kenneth C.

“…In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of…”
Get full text

Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma by Wilmoth, Jenai, Colson, Kathleen, Dubin, Franck, Kellam, Christine

“…Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple…”
Get full text

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma by Richardson, Paul G., Blood, Emily, Mitsiades, Constantine S., Jagannath, Sundar, Zeldenrust, Steven R., Alsina, Melissa, Schlossman, Robert L., Rajkumar, S. Vincent, Desikan, K. Raman, Hideshima, Teru, Munshi, Nikhil C., Kelly-Colson, Kathleen, Doss, Deborah, McKenney, Mary L., Gorelik, Svetlana, Warren, Diane, Freeman, Andrea, Rich, Rebecca, Wu, Anfang, Olesnyckyj, Marta, Wride, Kenton, Dalton, William S., Zeldis, Jerome, Knight, Robert, Weller, Edie, Anderson, Kenneth C.

“…This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were…”
Get full text

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma by Richardson, Paul, Mitsiades, Constantine, Colson, Kathleen, Reilly, Eileen, McBride, Laura, Chiao, Judy, Sun, Linda, Ricker, Justin, Rizvi, Syed, Oerth, Carol, Atkins, Barbara, Fearen, Ivy, Anderson, Kenneth, Siegel, David

“…A Phase I trial (NCT00109109) of oral vorinostat 200, 250 or 300 mg twice daily for 5 days week 4-week cycle or 200, 300, or 400 mg twice daily for 14 days…”
Get full text

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts by Nadeem, Omar, Mo, Clifton C, Laubach, Jacob P., Bianchi, Giada, Redd, Robert, Barth, Peter, Bayliss, Trevor J., Sanchorawala, Vaishali, Shune, Leyla, Distaso, Alexandra, Dalton, Virginia, Sperling, Adam S, Amweg, Laura, McKenney, Mary, Colson, Kathleen, Millard, Ella L, Hou, Isabella, Savell, Alexandra, Masone, Kelly, Munshi, Nikhil C., Ghobrial, Irene M., Anderson, Kenneth, Richardson, Paul G.

“…Introduction: Treatment of relapsed and refractory multiple myeloma (RRMM) continues to evolve as most patients are lenalidomide (LEN) refractory at the time…”
Get full text

Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma by Laubach, Jacob, Tuchman, Sascha Alexander, Rosenblatt, Jacalyn, Redd, Robert, Colson, Kathleen, Motta, Ashley, Fitzpatrick, Kathleen, Weller, Edie, Richardson, Paul G.

“…Abstract only…”
Get full text

Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma by Faiman, Beth, Doss, Deborah, Colson, Kathleen, Mangan, Patricia, King, Tracy, Tariman, Joseph, Board
, and

Get full text

A Focus on Special Populations in Relapsed Multiple Myeloma by Steinbach, DNP, APRN, Mary, Colson, RN, BSN, BS, Kathleen, Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, Beth

“…The overall care of patients with multiple myeloma can present similar challenges. However, disparities in health care require that providers consider each…”
Get full text

Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma by Faiman, Beth, Doss, Deborah, Colson, Kathleen, Mangan, Patricia, King, Tracy, Tariman, Joseph D

“…A majority of patients with multiple myeloma experience damage to the kidneys and peripheral nerves either at diagnosis or throughout the disease. Symptoms of…”
Get full text

Enhancing care and managing side effects in patients receiving bortezomib by Colson, Kathleen

Get more information

Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board by Miceli, Teresa S, Colson, Kathleen, Faiman, Beth M, Miller, Kena, Tariman, Joseph D

“…About 90% of individuals with multiple myeloma will develop osteolytic bone lesions from increased osteoclastic and decreased osteoblastic activity. Severe…”
Get full text

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma by Richardson, Paul, Jagannath, Sundar, Colson, Kathleen

“…Bortezomib (Velcade, Millennium) is the first proteasome inhibitor to be used in clinical practice and is indicated for the treatment of multiple myeloma…”
Get more information

Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board by Miceli, Teresa, Colson, Kathleen, Gavino, Maria, Lilleby, Kathy

“…Novel therapies for multiple myeloma include the immunomodulatory drugs lenalidomide and thalidomide and the proteasome inhibitor bortezomib, which have…”
Get full text